The current week (Jul 25-29) will be witness to a plethora of earnings releases as most of the bigwigs are lined up to report their quarterly numbers. Almost 1000 companies are slated to report their financial numbers, including 189 S&P 500 members.
We note that 126 S&P companies have already disclosed their numbers, with 70.6% of them beating the EPS estimates and 55.6% managing to clock a revenue beat.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 3.4% (slightly better than the earlier estimated decline of 5.4%) from the year-ago quarter. Also, revenues are estimated to decline 0.5%.
Medical is one of the seven sectors in the S&P 500 cohort that is expected to register earnings growth in the second quarter. The sector is estimated to report earnings growth of 1.8% on revenue improvement of 7.7%.
Dental is an important component of the Medical sector and is expected follow the same earnings growth trajectory in the quarter.
Here, we take a look at four Dental stocks set to report earnings on Jul 27:
McKesson Corporation (MCK - Free Report) , a major player in the pharmaceutical and medical supplies distribution market, is set to report its first-quarter fiscal 2017 results, after the market close. We expect McKesson to beat earnings as it has a favorable combination of Zacks Rank #2 (Buy) and Earnings ESP of +1.20%.
This is because, as per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Notably, McKesson has recorded excellent returns from the business units of distribution-solutions, pharmaceutical services in North America and Medical-Surgical distribution and services. Moreover, the collaborations with Biologics and Vantage Oncology and Change Healthcare Holdings are significant growth drivers. (Read more: McKesson Q1 Earnings: Stock Likely to Beat?)
Laboratory Corporation of America Holdings (LH - Free Report) , popularly known as LabCorp, is scheduled to report its second-quarter results, before the opening bell. New test launches, test menu enhancement and geographic footprint expansion are the key growth drivers for the company, in our view.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
We also note that LabCorp’s results compared favourably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 1.38%.
However, our model had earlier predicted a beat for LabCorp (Read more: Will LabCorp Beat Earnings Estimates in Q2?).
After market close, CONMED Corporation (CNMD - Free Report) is set to report second-quarter earnings. The company is expected to gain from the rapid adoption of the AirSeal system. However, Orthopedic Surgery sales and Surgical Visualization sales remain unsatisfactory, which is likely to dent growth for the company.
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%.
Merit Medical Systems Inc (MMSI - Free Report) is a leading manufacturer and marketer of proprietary disposable devices is scheduled to report second-quarter earnings, after the closing bell.
The acquisition of the HeRO Graft product line (early February), establishments of new facility in Mexico and approval of the Corvocet Biopsy System are the key positives.
Nevertheless, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
We also note that Merit Medical System’s results compared favorably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 10.17%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The current week (Jul 25-29) will be witness to a plethora of earnings releases as most of the bigwigs are lined up to report their quarterly numbers. Almost 1000 companies are slated to report their financial numbers, including 189 S&P 500 members.
We note that 126 S&P companies have already disclosed their numbers, with 70.6% of them beating the EPS estimates and 55.6% managing to clock a revenue beat.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 3.4% (slightly better than the earlier estimated decline of 5.4%) from the year-ago quarter. Also, revenues are estimated to decline 0.5%.
Medical is one of the seven sectors in the S&P 500 cohort that is expected to register earnings growth in the second quarter. The sector is estimated to report earnings growth of 1.8% on revenue improvement of 7.7%.
Dental is an important component of the Medical sector and is expected follow the same earnings growth trajectory in the quarter.
Here, we take a look at four Dental stocks set to report earnings on Jul 27:
McKesson Corporation (MCK - Free Report) , a major player in the pharmaceutical and medical supplies distribution market, is set to report its first-quarter fiscal 2017 results, after the market close. We expect McKesson to beat earnings as it has a favorable combination of Zacks Rank #2 (Buy) and Earnings ESP of +1.20%.
This is because, as per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Notably, McKesson has recorded excellent returns from the business units of distribution-solutions, pharmaceutical services in North America and Medical-Surgical distribution and services. Moreover, the collaborations with Biologics and Vantage Oncology and Change Healthcare Holdings are significant growth drivers. (Read more: McKesson Q1 Earnings: Stock Likely to Beat?)
Laboratory Corporation of America Holdings (LH - Free Report) , popularly known as LabCorp, is scheduled to report its second-quarter results, before the opening bell. New test launches, test menu enhancement and geographic footprint expansion are the key growth drivers for the company, in our view.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
We also note that LabCorp’s results compared favourably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 1.38%.
However, our model had earlier predicted a beat for LabCorp (Read more: Will LabCorp Beat Earnings Estimates in Q2?).
After market close, CONMED Corporation (CNMD - Free Report) is set to report second-quarter earnings. The company is expected to gain from the rapid adoption of the AirSeal system. However, Orthopedic Surgery sales and Surgical Visualization sales remain unsatisfactory, which is likely to dent growth for the company.
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%.
Merit Medical Systems Inc (MMSI - Free Report) is a leading manufacturer and marketer of proprietary disposable devices is scheduled to report second-quarter earnings, after the closing bell.
The acquisition of the HeRO Graft product line (early February), establishments of new facility in Mexico and approval of the Corvocet Biopsy System are the key positives.
Nevertheless, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
We also note that Merit Medical System’s results compared favorably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 10.17%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LH - FREE
Get the latest research report on CNMD - FREE
Get the latest research report on MCK - FREE
Get the latest research report on MMSI - FREE